Healthcare Titans Expand Their Portfolios in Acquisition Deals

Roche has announced the $2.7 billion acquisition of Carmot Therapeutics, including that company’s three potential incretin obesity and diabetes drugs. Incretins are gut hormones that are secreted after food intake and play a role in modulating blood glucose by stimulating insulin secretion and suppressing appetite. Closing is expected to take place in the first quarter of 2024.

In another major acquisition, Bristol Myers Squibb (BMS) has expanded its collaboration with Avidity Biosciences — a biopharmaceutical company committed to delivering a new class of RNA therapeutics called antibody oligonucleotide conjugates. The deal is for global licensing and research on the discovery, development commercialization of multiple cardiovascular targets with potential payments of up to $2.3 billion.

And Johnson & Johnson MedTech has acquired Laminar, a privately-held medical device company focused on eliminating the left atrial appendage in patients with non-valvular atrial fibrillation for $400 million. Laminar will join Johnson & Johnson MedTech as part of Biosense Webster, a part of J&J that focuses on cardiac arrhythmia treatment.

To read the whole story, click here to subscribe.

Related Topics